Zogenix Reports Second Quarter 2014 Financial Results
05. August 2014 16:05 ET
|
Zogenix
Recent Business Highlights
Provided updated timeline for abuse deterrent formulations of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with sNDA for first candidate...
Zogenix Announces Departure of Chief Commercial Officer, Scott Shively
01. August 2014 16:05 ET
|
Zogenix
SAN DIEGO, Aug. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Zogenix Announces Conference Call and Webcast to Present Second Quarter 2014 Financial Results
22. Juli 2014 09:00 ET
|
Zogenix
SAN DIEGO, July 22, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board
17. Juli 2014 08:30 ET
|
Zogenix
SAN DIEGO, July 17, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System
14. Juli 2014 08:30 ET
|
Zogenix
SAN DIEGO, July 14, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the issuance of a new patent, US 8,734,384, from the United States Patent and Trademark Office (USPTO). The...
Zogenix Reports Positive Development on U.S. District Court Ruling
09. Juli 2014 08:30 ET
|
Zogenix
SAN DIEGO, July 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today commented on the order issued by the U.S. District Court in Massachusetts upholding its prior decision that imposing...
Zogenix Provides Update on Development of Abuse Deterrent Formulations of Zohydro(R) ER
02. Juli 2014 07:30 ET
|
Zogenix
SAN DIEGO, July 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced an update on its development programs focused on the introduction of abuse deterrent formulations of...
Zogenix to Present at Two Upcoming Conferences
16. Juni 2014 16:30 ET
|
Zogenix
SAN DIEGO, June 16, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
Zogenix Reports Granting of Inducement Awards
02. Juni 2014 18:40 ET
|
Zogenix
SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Zogenix Officers to Report Withholding of Shares
02. Juni 2014 09:00 ET
|
Zogenix
SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...